Takeda Announces New Assignments of Directors

June 28, 2018

Osaka, Japan, June 28, 2018 – Takeda Pharmaceutical Company Limited (TSE 4502) today announced new assignment of Directors. The details are as follows;

1.　New assignment of Non-Audit and Supervisory Committee Directors effective June 28, 2018

Name	Category		Current Role
Christophe Weber	Internal	Existing	Representative Director, President & Chief Executive Officer
Masato Iwasaki	Internal	Existing	Director, President, Japan Pharma Business Unit
Andrew Plump	Internal	Existing	Director, Chief Medical & Scientific Officer
Masahiro Sakane	External	Existing	External Director, Chair of the Board Meeting
Yoshiaki Fujimori	External	Existing	External Director
Emiko Higashi	External	Existing	External Director
Michel Orsinger	External	Existing	External Director
Toshiyuki Shiga	External	Existing	External Director

2.　New assignment of Audit and Supervisory Committee Directors effective June 28, 2018

Name	Category		Current Role
Yasuhiko Yamanaka	Internal	Existing	Director, Full-time Audit & Supervisory Committee member
Shiro Kuniya	External	Existing	External Director, Chairperson of Audit & Supervisory Committee
Jean-Luc Butel	External	Existing	External Director, Audit & Supervisory Committee member
Koji Hatsukawa	External	Existing	External Director, Audit & Supervisory Committee member

3.　New assignment of Non-Audit and Supervisory Committee Directors effective June 28, 2018;
　　-　Compensation committee : Toshiyuki Shiga (Chair), Yoshiaki Fujimori, Yasuhiko Yamanaka
　　-　Nomination committee : Masahiro Sakane (Chair), Emiko Higashi,
　　　　　　　　　　　　　　　　 Shiro Kuniya, Christophe Weber

Media Contact
Kazumi Kobayashi
Tel: +81-3-3278-2095
Email: [email protected]